share_log
Moomoo 24/7 ·  04/15 16:15

Oric Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1B Trial of Oric-114 in Patients With Mutated Nsclc

Oric Pharmicals宣佈在針對突變非小細胞肺癌患者的Oric-114的1B期試驗中,三個擴展隊列中首批患者給藥

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論